首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 171 毫秒
1.
IκB激酶(IKK复合体)是NF-κB信号转导途径成员之一,包括3个亚基:催化亚基IKKα、IKKβ和调节亚基IKKγ。无刺激时,NF-κB与抑制蛋白IκB家族的一个成员结合,或者与无活性前体(如p100)结合而以无活性形式存在。在外界信号如TNF-α或淋巴毒素β等刺激下,经过复杂的信号转导,IKK复合体被激活,导致IκB和(或)p100发生磷酸化,结果NF-κB被释放出来,进入细胞核内激活靶基因。最新研究发现在TNF-α刺激下,IKKα可直接进入细胞核内,通过催化组蛋白H3磷酸化进而激活特定NF-κB应答基因的表达。IKKα是首次发现的信号转导途径中直接进入细胞核内调节基因表达的上游成分,为NF-κB信号转导途径的研究开辟了新的道路。  相似文献   

2.
目的探讨内毒素(LPS)刺激大鼠肠黏膜微血管内皮细胞(RIMMVECs)后,乳酸(LA)调控NF-κB信号通路中磷酸化IκBα和NF-κB p65蛋白表达情况,肿瘤坏死因子α(TNF-α)和白细胞介素6(IL-6)mRNA表达情况,阐明乳酸发挥作用的最佳时间及其调控NF-κB信号通路的部位。方法提取RIMMVECs总蛋白和总RNA,用Western blotting检测NF-κB p65、IκBα及p-IκBα蛋白表达水平,用real-time PCR对TNF-α和IL-6 mRNA进行定量检测。结果乳酸能降低LPS诱导RIMMVECs分泌的TNF-α和IL-6 mRNA表达水平,并分别于24 h和3 h下调效果最明显;乳酸能抑制IκBα磷酸化及NF-κB转录活性,并于4~8 h达到最佳效果;乳酸发挥作用部位是抑制信号通路中IκBα磷酸化。结论乳酸通过抑制IκBα磷酸化而阻断NF-κB的激活,抑制下游炎性因子表达,进而发挥出很好的预防炎症效果。  相似文献   

3.
前期研究结果表明,乙型肝炎病毒X蛋白结合蛋白(hepatitis B virus X-interacting protein,HBXIP)具有促进细胞增殖的作用.为了进一步阐明其分子机制,观察了HBXIP对核因子κB(NF-κB)转录活性的影响.实验中通过基因共转染将NF-κB报告基因质粒pNF-κB-Luc和HBXIP真核表达载体pcDNA3-hbxip导入人肝癌H7402细胞系中,进行荧光素酶活性分析.结果显示:H7402细胞过表达HBXIP后NF-κB的转录活性明显增强;此外,基因转染后经免疫印迹检测显示,与NF-κB二聚体结合的抑制亚基IκBα的磷酸化水平明显增加;同时,提取H7402细胞的核蛋白,然后应用免疫印迹检测细胞核中p65/NF-κB的水平.结果显示,H7402细胞中HBXIP过表达后细胞核中p65/NF-κB的水平明显增加.当应用RNA干扰技术抑制了细胞内源性的HBXIP基因表达后,则出现与上述结果相反的效果.上述结果提示,HBXIP可增加核内p65/NF-κB蛋白水平,进而发挥NF-κB促转录调控的作用.因此,HBXIP可通过调控NF-κB信号途径而促进细胞增殖.  相似文献   

4.
本研究检测了绝经后骨质疏松症妇女的肿瘤坏死因子-α(TNF-α)和雌激素水平,并探讨了TNF-α对破骨前体细胞RAW264.7中破骨细胞标志物核因子κB受体激活因子(nuclear factor kappa-B, RANK)、组织蛋白酶K (Cathepsin K, CTSK)和凝血酶受体激活肽(thrombin receptor activating peptide, TRAP)以及核因子-κB (NF-κB)亚基(p65)和NF-κB抑制蛋白(IκBα)的影响。研究结果表明,绝经后骨质疏松症患者的TNF-α水平显著升高,而雌二醇水平显著降低。核因子κB受体激活因子配体(receptor activator for NF-κBligand, RANKL)处理1周后,破骨前体细胞RAW264.7中破骨细胞标志物RANK、CTSK和TRAP的mRNA和蛋白高度表达。与RANKL对照组相比,TNF-α处理可上调RANK、CTSK和TRAP m RNA的表达。但是,仅TNF-α不能诱导培养的RAW264.7细胞分化为破骨细胞成。TNF-α以剂量依赖性方式诱导NF-κB亚基p65和IκBα磷酸化,而NF-κB抑制剂处理则有效降低了RANK和TRAP的表达。本研究结论表明,绝经后骨质疏松症中TNF-α通过激活NF-κB来促进RANKL诱导的破骨细胞形成。  相似文献   

5.
目的 通过检测鼻息肉组织中核因子кB(NF-кB)的活化及白介素-8(IL-8)的转录水平,探讨鼻息肉组织中NF-кB的活化对IL-8转录的影响及临床意义.方法分别应用凝胶电泳迁移实验法、蛋白免疫印迹法、免疫组织化学法及逆转录聚合酶链反应法检测47例鼻息肉患者(鼻息肉组)的息肉组织中NF-κB的活性及其p65亚基蛋白水平、IL-8的组织定位及转录水平;以22例鼻中隔手术患者中鼻甲黏膜组织作为阴性对照(对照组);对NF-кB的活性及其p65亚基蛋白水平与IL-8的转录水平进行Pearson's相关性分析.结果 EMSA测得鼻息肉组患者息肉组织中NF-κB的活性(216.51±17.33)较对照组(63.57±5.26)显著增高(P<0.01);Western Blot 测得鼻息肉组NF-κB亚基p65 蛋白的水平(153.72±9.15)较对照组(73.92±6.74)显著增高(P<0.05);半定量RT-PCR 测得IL-8 mRNA的转录水平(0.95±0.08)也显著高于对照组(0.23±0.03)(P<0.05);Pearson's相关性分析结果提示:鼻息肉组患者息肉组织中NF-κB的活性及其p65亚基蛋白水平与IL-8的转录水平呈显著正相关性(r值分别为 0.78 & 0.53,均P<0.01).结论 IL-8是鼻息肉组织中NF-кB激活后所分泌的重要的炎性细胞因子,NF-кB和IL-8引起的局部微环境的改变可能是鼻息肉发病的重要因素.  相似文献   

6.
IκB激酶的激活及其在NF-κB活化过程中的作用   总被引:3,自引:0,他引:3  
在NF-κB二聚体活化过程中,IκB激酶(IKK)通过对抑制性蛋白κB(IκBs)的磷酸化而扮演关键的角色.IKK复合物在胞浆内有多种存在形式,其中,IKK-α、IKK-β两者氨基酸序列52%的同源性,空间构象相似,常为催化亚单位,而IKK-γ则为调节亚单位,它们以不同的方式活化IκBs.核因子κB诱导激酶(NIK)与丝裂原活化蛋白激酶激酶激酶-1(MEKK1)均为IKK的上游激酶,NIK可引起IKK-α Ser176、IKK-β相应位点的磷酸化,而MEKK1主要引起IKK-β的活化.通过级联反应,使IκBs磷酸化而与NF-κB解离,致使NF-κB被激活并易位入核,启动免疫及炎症相关的基因转录.  相似文献   

7.
低氧对巨噬细胞分泌TNF-α和IL-6的影响及其机制   总被引:3,自引:0,他引:3  
目的:观察低氧对巨噬细胞(Mφ)前炎症因子TNF-α和IL-6分泌的影响及其机制.方法:收集分离小鼠腹腔Mφ,建立Mφ的低氧(1% O2,5%CO2)培养模型,并用非特异性酯酶染色法进行鉴定;ELISA法检测上清液中TNF-α和IL-6的含量;RT-PCR法检测TNF-α和IL-6的转录物水平;用Western blot法检测Mφ核内NF-κB的激活量;通过在培养液中加入氢化可的松(5 mg/L),观察低氧时TNF-α和IL-6分泌量的变化.结果:TNF-α和IL-6分泌量在低氧12 h时明显增加(P<0.01);低氧6 h时,TNF-α mRNA和IL-6 mRNA表达量明显高于对照组(P<0.01);M中核内NF-κB的激活量在低氧2 h时明显增高(P<0.05),低氧5 h内持续存在;而当培养液中加入氢化可的松抑制NF-κB活性后,TNF-α和IL-6的分泌水平无明显变化.结论:低氧可通过核转录因子NF-κB途径促进细胞因子TNF-α和IL-6基因的表达和分泌.  相似文献   

8.
核转录因子-κB(NF-κB)是一种广泛存在于体内多种细胞的核转录因子。静息状态下,NF-κB二聚体与其抑制蛋白IκB结合而存在于胞质中。当细胞受到外界刺激时,IκB磷酸化,使NF-κB活化进入细胞核,调节相应靶细胞的表达。本文对NF-κB家族、分子生物学特性及其在口腔疾病中发生和治疗中分子机制进行探讨,为口腔疾病致病机理以及探寻其"干预治疗"的关键靶点提供理论依据和新思路。  相似文献   

9.
核转录因子kappa B(NF-κB)是细胞中一种重要的转录调节因子,它参与细胞炎症以及免疫应答等重要生命活动。NF-κB转录活化受到磷酸化、乙酰化、甲基化和泛素化等多种翻译后修饰调控。近年来随着对NF-κB亚基泛素化调控研究的深入,发现其在终止NF-κB活性和与它相关的转录反应中扮演着重要角色。本文将重点围绕NF-κB亚基的泛素化调节研究进展作一综述。  相似文献   

10.
利用不同转移潜能肝癌细胞系探讨热休克蛋白27(HSP27)参与肝癌细胞转移潜能形成的可能分子机制.细胞免疫荧光技术、RT-PCR和免疫印迹技术显示,HSP27在转移潜能不同的肝癌细胞Hep3B、MHCC97L和MHCC97H中定位于细胞浆,亦可见于细胞核,HSP27 mRNA和蛋白质的表达水平与肝癌细胞转移潜能呈正相关.高转移潜能肝癌细胞系MHCC97H的HSP27 RNA干扰试验结果显示,HSP27 RNA干扰后MHCC97H的侵袭(MHCC97H组:21.36±2.92;对照RNAi组:19.88±2.23;RNAi组:11.40±2.05)、运动能力(MHCC97H组:26.35±3.29;对照RNAi组:24.43±3.17;RNAi组:10.92±2.27)明显减弱,细胞凋亡显著增加(MHCC97H组:15.12%;对照RNAi组:17.56%;RNAi组:27.64%).同时进行信号转导基因芯片检测发现,HSP27干扰后核因子κB(NF-κB)通路抑制,并且免疫印迹显示细胞核内活化的NF-κBp65减少,细胞内磷酸化IκBα降低.另外,免疫共沉淀检测发现,在肝癌细胞内HSP27可与IKKβ、IκBα共沉淀,且在HSP27RNA干扰后IKKβ与IKKα结合能力下降.这些结果提示,HSP27可能通过参与细胞内NF-κB通路的激活,影响细胞凋亡和细胞运动,在肝癌细胞侵袭转移过程中发挥作用.  相似文献   

11.
12.
13.
14.
15.
NF-kappaB activation is reciprocally regulated by RelA/p65 acetylation and deacetylation, which are mediated by histone acetyltransferases (HATs) and deacetylases (HDACs). Here we demonstrate that in leukemia cells, NF-kappaB activation by the HDAC inhibitors (HDACIs) MS-275 and suberoylanilide hydroxamic acid was associated with hyperacetylation and nuclear translocation of RelA/p65. The latter events, as well as the association of RelA/p65 with IkappaBalpha, were strikingly diminished by either coadministration of the IkappaBalpha phosphorylation inhibitor Bay 11-7082 (Bay) or transfection with an IkappaBalpha superrepressor. Inhibition of NF-kappaB by pharmacological inhibitors or genetic strategies markedly potentiated apoptosis induced by HDACIs, and this was accompanied by enhanced reactive oxygen species (ROS) generation, downregulation of Mn-superoxide dismutase and XIAP, and c-Jun N-terminal kinase 1 (JNK1) activation. Conversely, N-acetyl L-cysteine blocked apoptosis induced by Bay/HDACIs by abrogating ROS generation. Inhibition of JNK1 activation attenuated Bay/HDACI lethality without affecting NF-kappaB inactivation and ROS generation. Finally, XIAP overexpression dramatically protected cells against the Bay/HDACI regimen but failed to prevent ROS production and JNK1 activation. Together, these data suggest that HDACIs promote the accumulation of acetylated RelA/p65 in the nucleus, leading to NF-kappaB activation. Moreover, interference with these events by either pharmacological or genetic means leads to a dramatic increase in HDACI-mediated lethality through enhanced oxidative damage, downregulation of NF-kappaB-dependent antiapoptotic proteins, and stress-related JNK1 activation.  相似文献   

16.
17.
18.
19.
The role of NF-kappaB in cardiac physiology and pathophysiology has been difficult to delineate due to the inability to specifically block NF-kappaB signaling in the heart. Cardiac-specific transgenic models have recently been developed that repress NF-kappaB activation by preventing phosphorylation at specific serine residues of the inhibitory kappaB (IkappaB) protein isoform IkappaBalpha. However, these models are unable to completely block NF-kappaB because of a second signaling pathway that regulates NF-kappaB function via Tyr42 phosphorylation of IkappaBalpha. We report the development of transgenic (3M) mouse lines that express the mutant IkappaBalpha(S32A,S36A,Y42F) in a cardiac-specific manner. NF-kappaB activation in cardiomyopathic TNF-1.6 mice is completely blocked by the 3M transgene but only partially blocked (70-80%) by the previously described double-mutant 2M [IkappaBalpha(S32A,S36A)] transgene, which demonstrates the action of two proximal pathways for NF-kappaB activation in TNF-alpha-induced cardiomyopathy. In contrast, after acute stimuli including administration of TNF-alpha and ischemia-reperfusion (I/R), NF-kappaB activation is blocked in both 2M and 3M transgenic mice. This result suggests that phosphorylation of the regulatory Ser32 and Ser36 predominantly mediates NF-kappaB activation in these situations. We show that infarct size after I/R is reduced by 70% in 3M transgenic mice, which conclusively demonstrates that NF-kappaB is involved in I/R injury. In summary, we have engineered novel transgenic mice that allow us to distinguish two major proximal pathways for NF-kappaB activation. Our results demonstrate that the serine and tyrosine phosphorylation pathways are differentially activated during different pathophysiological processes (cardiomyopathy and I/R injury) and that NF-kappaB contributes to infarct development after I/R.  相似文献   

20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号